Associate Director/Director
Braveheart Bio
Associate Director/Director
Braveheart Bio
Develops cardiac myosin inhibitors for HCM
About us:
Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity.
With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area.
The role:
Position reports to the Head of Medical Affairs. This individual will own the publications function for BHB-1893, leading the strategy, planning, and execution of a multi-year publication and congress plan that builds the body of evidence supporting the global development and future launch of BHB-1893 for obstructive and non-obstructive hypertrophic cardiomyopathy (oHCM and nHCM). This is a highly cross-functional and hands-on role that will serve as the central point of coordination for the publications strategy and execution. The individual will drive publications from concept through submission and publication, ensuring alignment, scientific quality, and timely delivery across the portfolio. This role will also be responsible for medical affairs reactive scientific communications supporting the global development and future launch of BHB-1893 for hypertrophic cardiomyopathy (HCM). All activities will reflect the highest standards of scientific integrity and remain fully compliant with GPP, ICMJE, and applicable regulatory and industry guidelines.
Key responsibilities:
Publication strategy & planning
Congress & data dissemination
Cross-functional & external collaboration
Reactive scientific content development
Governance, compliance & operations
Required experience & skills:
Preferred experience & skills:
Base Salary Range: $175,000 - $245,000
This role is also eligible for a competitive total rewards package, which may include an annual bonus, equity, and a comprehensive benefits offering.
We are an equal opportunity employer.
We are committed to inclusion and diversity, and we do not discriminate on the basis of race, gender, religion, gender, sexual orientation, age, color, marital status, veteran status, disability status, national origin, or any characteristic protected under applicable law.
Braveheart participates in the federal E‑Verify program to confirm employment authorization for all new hires.
To learn more about E-Verify please review this poster.
Develops cardiac myosin inhibitors for HCM
Braveheart Bio develops therapies for hypertrophic cardiomyopathy by in-licensing promising drug candidates and advancing them through late-stage clinical trials. Its lead drug, BHB-1893, is a selective small-molecule cardiac myosin inhibitor licensed from Hengrui Pharma for ex-China rights, designed to reduce contractility in heart cells and improve heart performance. The company differentiates itself by pursuing a best-in-class profile with potential improvements in efficacy, safety, and dosing, supported by a high-profile leadership team and investors. Its goal is to bring an approved, globally accessible therapy for HCM that delivers meaningful clinical benefit.
Explore more opportunities at Braveheart Bio